Fact sheet summarizing Federal agency guidance, regulatory changes, and resources to ensure that SUD prevention, treatment, and recovery support services continue to be available during the COVID-19 pandemic.
Join Tanya Lord, PhD, MPH, Lara Weinstein, MD, MPH, DrPH, and Joshua Carter, PsyD, as they discuss the impact of the COVID-19 pandemic on the patient care experience and preparing patients to adapt to the use of telehealth for effective MOUD treatment.
Join Nickolas Zaller, PhD, Nicolas Terry, LLM, Jodi Manz, MSW, and Lauren Brinkley-Rubinstein, PhD as they review the impact of the COVID-19 pandemic on the treatment of OUD for those incarcerated and the importance of ensuring a safe release to optimize continuity of care.
Legal analysis of four hypothetical scenarios for prescribing buprenorphine for opioid use disorder in the United States during the novel coronavirus outbreak.
Details concerning the additional challenges faced by the SUD (and OUD) population at this time, the positive ameliorative steps taken by federal, state, and local governments, and recommended additional steps that are needed.
Join Jocelyn Guyer, MPA, and Jodi Manz, MSW, as they review emerging federal and state actions and opportunities (including case studies) to assist those with OUD through the COVID-19 pandemic.